drugset / Trial / NCT00002988

Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma

NCT00002988

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus carmustine in treating patients who have recurrent primary malignant glioma.

Timeline

Start
1997-04
Primary completion
2000-11
Completion
2000-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule Intravenous
Subject carmustine Small molecule Intravenous